One Heart to Care for

NCT ID: NCT04753398

Last Updated: 2021-02-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open randomized clinical trial with two study arms. One group, receiving usual care for heart failure, will be compared to another group, receiving usual care plus active telemonitoring interference.

When leaving the hospital, the usual care arm receives a document with a predefined medication scheme and advice for the general practitioner (like it is currently done in usual care). Besides the normal consultations at 2 and 5 weeks, no active interactions take place between the study nurse and the patient.

The telemonitoring interference in the other study arm consists of an automatic blood pressure device and medication dispenser that transmit data to a central platform. During the first 12 weeks, the nurse of the call center will give incentive for medication up titration on the basis of the available data. Before up titration can be done, the patient needs to take blood pressure measurements 3 times in the morning and 3 times in the evening and at least 6 measurements a week.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Telemonitoring group

Additional telemonitoring devices: Blood Pressure Monitor, medication dispenser, telemonitoring technology

Group Type EXPERIMENTAL

Blood Pressure Monitor, medication dispenser, telemonitoring technology

Intervention Type DEVICE

The telemonitoring interference in the telemonitoring arm consists of an automatic blood pressure device and medication dispenser that transmit data to a central platform.

Control group

usual care, without telemonitoring

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood Pressure Monitor, medication dispenser, telemonitoring technology

The telemonitoring interference in the telemonitoring arm consists of an automatic blood pressure device and medication dispenser that transmit data to a central platform.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Telemedicine remote monitoring remote follow-up

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \- Age ≥ 50
* Patient has to be followed in Ziekenhuis Oost-Limburg or Jessa Ziekenhuis Hasselt
* The patient has to be able to live independently or in a service flat
* The diagnosis of heart failure or severe myocardial infarction has to be done after September 1, 2013 according to:

* Left ventricular ejection fraction (LVEF) \<40%
* eGFR\>30ml/min/kg
* Treatment minimally with ACE-I and BB
* The general practitioner had to give his approval for the installation of telemonitoring On the basis of an interview between the heart failure nurse and patient, one will decide if the patient is eligibil to join the study. The patient also needs to speak sufficient Dutch to be communicative about his/her medical condition.

Exclusion Criteria

* Reversible form of heart failure
* Heart failure due to severe aortic stenosis
* eGFR less than 30ml/min/kg
* Presence of a cardiac resynchronization therapy (CRT) device
* Palliative status following the RIZIV guidelines or according to the assessment of the cardiologist (\<1 year)
* Patients staying in a nursing or retirement home
* Active treatment with either ACE-I/ARB or BB
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ziekenhuis Oost-Limburg

OTHER

Sponsor Role collaborator

WGK Limburg

UNKNOWN

Sponsor Role collaborator

Hasselt University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pieter Vandervoort

prof. dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pieter Vandervoort, prof. dr.

Role: PRINCIPAL_INVESTIGATOR

Ziekenhuis Oost-Limburg

Brenda Aendekerk, MSc

Role: STUDY_DIRECTOR

Wit Gele Kruis Limburg, Genk, Belgium

Valerie Storms, dr.

Role: STUDY_DIRECTOR

Hasselt University

Lars Grieten, dr.

Role: PRINCIPAL_INVESTIGATOR

Hasselt University

Christophe Smeets, MSc

Role: STUDY_CHAIR

Hasselt University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ziekenhuis Oost-Limburg

Genk, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

13/085U

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Congestive Heart Failure Outreach Program
NCT00371085 COMPLETED PHASE4
A Preliminary Study for INFORMED
NCT05585125 ENROLLING_BY_INVITATION PHASE4